Mankind Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Mankind Pharma Ltd reported a 3.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 18.9%.
• Its expenses for the quarter were up by 1.7% QoQ and 35.4% YoY.
• The net profit increased 17.0% QoQ and decreased 21.1% YoY.
• The earnings per share (EPS) of Mankind Pharma Ltd stood at 12.38 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mankind Pharma Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of a wide range of pharmaceutical products. The company focuses on producing affordable medications across various therapeutic segments, including antibiotics, anti-infectives, cardiovascular, gastrointestinal, and dermatological products. Mankind Pharma has established a significant presence in India and is expanding its footprint globally. As of the latest information available up to October 2023, the company has continued to innovate and increase its market share within the pharmaceutical sector. However, specific details on recent developments post this period are not available.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Mankind Pharma Ltd reported a total income of ₹3789.03 crores. This represents a sequential increase of 3.8% compared to the first quarter of the same fiscal year (Q1FY26), where the total income was ₹3650.23 crores. On a year-over-year basis, the revenue showed a robust growth of 18.9% compared to the second quarter of the previous fiscal year (Q2FY25), when the total income stood at ₹3185.94 crores. This increase in total income reflects the company's ongoing efforts to enhance its sales and distribution network, as well as its ability to capture a larger market share in the pharmaceutical sector.

Profitability

During Q2FY26, Mankind Pharma Ltd achieved a profit before tax of ₹621.70 crores, which marks a 15.7% improvement over the previous quarter (Q1FY26), where the profit before tax was ₹537.32 crores. However, when compared to the same quarter in the previous fiscal year (Q2FY25), there was a decline of 26.6% from ₹846.75 crores. The tax expense for Q2FY26 was ₹103.84 crores, up 8.3% from the previous quarter, but down 45.5% year-over-year. The profit after tax for Q2FY26 was ₹520.18 crores, a 17.0% increase from Q1FY26, yet a 21.1% decrease compared to Q2FY25. Earnings per share in Q2FY26 were ₹12.38, showing a quarterly rise of 16.8% but a yearly decrease of 24.0% from ₹16.28 in Q2FY25.

Operating Metrics

The total expenses for Mankind Pharma Ltd in Q2FY26 were reported at ₹3167.33 crores, representing a 1.7% increase from ₹3112.91 crores in Q1FY26. This marks a more significant year-over-year rise of 35.4% from ₹2339.19 crores in Q2FY25. The company's ability to manage its expenses while achieving revenue growth is crucial for its financial health. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not directly provided in the data, indicating a need for additional information to calculate these metrics accurately. The observed trends in expenses relative to income highlight the dynamics of the company's operational efficiency and cost management strategies.